Lipid nanoparticles (LNPs) are widely used as carriers to deliver multiple types of therapeutics. Many formulations for parenteral delivery contain cationic components with proprietary information that require additional safety evaluation, including genotoxicity. Inotiv has extensive experience with the modified genetox safety assessment requirements for this type of drug delivery product.
Download your copy of the presentation to learn more about:
- What is involved in the genotoxicity testing of LNP
- Limitations on the testing of LNP
- Types of genetic toxicology assays to perform on LNP
- FDA guidance on testing of LNP
